Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255858 | 0.83 | KMT2A (0.52) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10255493 | 0.83 | KMT2A (0.40) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL2493587 | 0.81 | ATR (0.46) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL10255365 | 0.80 | NPC1 (0.44) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10256552 | 0.80 | HSD17B10 (0.44) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10255406 | 0.80 | MAPT (0.42) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10255382 | 0.79 | MAPK1 (0.43) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10256692 | 0.78 | MAPK1 (0.42) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL10255565 | 0.76 | ATR (0.41) | MEN1LMNAMAPK1KMT2AKDM4E | |
| SCHEMBL16420626 | 0.74 | RAB9A (0.58) | MEN1MAPK1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | MEN1 2659/4885LMNA 804/4885MAPK1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.